Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
- MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
- Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
- Japan Approves Add’l Indications for Taltz, Lucentis and More
November 25, 2019
- No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
- MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
- MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
- PIC/S Reports State of Discussions on Data Integrity Guidance in Japan Meeting: MHLW
November 25, 2019
- US, European Pharma Groups Push LDP to Expedite Vaccine Policies
November 22, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- MHLW Proposes 3-Stage Plan to Develop Systems to Promote Genomic Medicine for Intractable Diseases
November 22, 2019
- Chuikyo Discussing Admission Fee for Schizophrenia Patients on Drug Clozapine, Eyeing Transition to Home
November 21, 2019
- MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
- Japan Grants Orphan Status to Tepotinib and More
November 20, 2019
- 83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW
November 20, 2019
- Regenerative Medicine Industry Calls for Appropriate Reward for Innovation: Public-Private Confab
November 19, 2019
- MHLW Panel to Discuss Eisai’s Insomnia Med and More on Nov. 29, Skips Ono’s Cachexia Drug Again
November 18, 2019
- Inpatient Generic Use Tops 80% in Japan Hospitals: Chuikyo
November 18, 2019
- 8.2% of Hospitals Have Formularies: Chuikyo Survey
November 18, 2019
- MHLW Orders Label Revisions for Xtandi, Erleada to Include Interstitial Lung Disease to ADR List
November 18, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…